← Back to patent-cliff list
Paclitaxel cationic liposomes for injection(CSPC Zhongqi Pharma)
Tier C — Watch / tradePaclitaxel cationic liposomes for injection(CSPC Zhongqi Pharma)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Tubulin
Indications (approved)：Colorectal cancer, Hepatocellular carcinoma, Solid tumour, Breast cancer
Regional status
US
-
EU
-
China
Phase III
2025-06-02
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Paclitaxel cationic liposomes for injection(CSPC Zhongqi Pharma)?
Approved indications include: Colorectal cancer, Hepatocellular carcinoma, Solid tumour, Breast cancer.
When does the Paclitaxel cationic liposomes for injection(CSPC Zhongqi Pharma) patent expire?
No public expiry year is available for Paclitaxel cationic liposomes for injection(CSPC Zhongqi Pharma) yet; this page updates once verified.
How do I get a quote for Paclitaxel cationic liposomes for injection(CSPC Zhongqi Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30